🚀 VC round data is live in beta, check it out!
Sinocare Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sinocare and similar public comparables like Ramsay Santé, Medartis, Shinva, Kuros Biosciences and more.
Sinocare Overview
About Sinocare
Sinocare Inc operates in the healthcare industry. It is engaged in the development, manufacturing, and marketing of diagnosis testing products for people with chronic diseases and healthcare professionals. Its product range covers household blood glucose meter, medical blood glucose meter, urinary microalbumin test strip and blood lipid uric acid products. In addition, the company also provides diabetes management information systems.
Founded
2002
HQ
Employees
N/A
Website
Financials (LTM)
EV
$1B
Sinocare Financials
Sinocare reported last 12-month revenue of $705M and EBITDA of $70M.
In the same LTM period, Sinocare generated $70M in EBITDA and $26M in net income.
Revenue (LTM)
Sinocare P&L
In the most recent fiscal year, Sinocare reported revenue of $651M and EBITDA of $97M.
Sinocare expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $705M | XXX | $651M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $357M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $70M | XXX | $97M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $26M | XXX | $48M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 7% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sinocare Stock Performance
Sinocare has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Sinocare's stock price is $2.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSinocare Valuation Multiples
Sinocare trades at 1.8x EV/Revenue multiple, and 18.2x EV/EBITDA.
EV / Revenue (LTM)
Sinocare Financial Valuation Multiples
As of April 20, 2026, Sinocare has market cap of $1B and EV of $1B.
Equity research analysts estimate Sinocare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sinocare has a P/E ratio of 49.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 18.2x | XXX | 13.2x | XXX | XXX | XXX |
| EV/EBIT | 57.1x | XXX | 16.6x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.6x | XXX | XXX | XXX |
| P/E | 49.9x | XXX | 27.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 19.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sinocare Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sinocare Margins & Growth Rates
Sinocare's revenue in the last 12 month grew by 6%.
Sinocare's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sinocare's rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sinocare Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | (41%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 36% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sinocare Public Comps
See public comps and valuation multiples for other Medical Devices and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sinocare | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Santé | XXX | XXX | XXX | XXX | XXX | XXX |
| Medartis | XXX | XXX | XXX | XXX | XXX | XXX |
| Shinva | XXX | XXX | XXX | XXX | XXX | XXX |
| Kuros Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Staar Surgical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sinocare M&A Activity
Sinocare acquired XXX companies to date.
Last acquisition by Sinocare was on XXXXXXXX, XXXXX. Sinocare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sinocare
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSinocare Investment Activity
Sinocare invested in XXX companies to date.
Sinocare made its latest investment on XXXXXXXX, XXXXX. Sinocare invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sinocare
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sinocare
| When was Sinocare founded? | Sinocare was founded in 2002. |
| Where is Sinocare headquartered? | Sinocare is headquartered in China. |
| Is Sinocare publicly listed? | Yes, Sinocare is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Sinocare? | Sinocare trades under 300298 ticker. |
| When did Sinocare go public? | Sinocare went public in 2012. |
| Who are competitors of Sinocare? | Sinocare main competitors are Ramsay Santé, Medartis, Shinva, Kuros Biosciences. |
| What is the current market cap of Sinocare? | Sinocare's current market cap is $1B. |
| What is the current revenue of Sinocare? | Sinocare's last 12 months revenue is $705M. |
| What is the current revenue growth of Sinocare? | Sinocare revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Sinocare? | Current revenue multiple of Sinocare is 1.8x. |
| Is Sinocare profitable? | Yes, Sinocare is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sinocare? | Sinocare's last 12 months EBITDA is $70M. |
| What is Sinocare's EBITDA margin? | Sinocare's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Sinocare? | Current EBITDA multiple of Sinocare is 18.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.